It has been an amazing year for patients with sickle cell disease (SCD) with two new drug approvals in recent weeks, and hopes are also building that bluebird bio’s LentiGlobin gene therapy ...

the gene therapy has been given the all-clear by bluebird’s scientists after reviewing the case of AML that emerged in a trial of the drug in sickle cell disease. If regulators such as the FDA ...

bluebird bio, Inc. (NASDAQ ... LYFGENIA is a one-time gene therapy to treat sickle cell disease in individuals 12 years of age or older and a history of vaso-occlusive events (VOEs).

Vertex Pharmaceuticals and bluebird bio have entered into ... Cost is a big issue with gene therapy for sickle cell; the list price for exagamglogene autotemcel is $2.2 million, while ...

A new gene editing treatment has been approved for use in the NHS, which will help treat sickle cell disease patients ...

But for a brief moment on a recent December morning, Wedam, 19, who has sickle ... gene therapy treatment. At Children’s National — which was ahead of the curve after it participated in ...

Accumulation of clots causes some of the most severe symptoms of sickle cell disease, including strokes, kidney failure, ...

Exagamglogene autotemcel (exa-cel) gene therapy offers a potential cure for severe sickle cell disease, now available on NHS.

With a dedicated focus on severe genetic diseases, bluebird has the largest and deepest ex-vivo gene therapy data set in the field, with industry-leading programs for sickle cell disease ...

Opinions expressed by Forbes Contributors are their own. Joshua Cohen is a Boston-based writer who covers health policy. The Biden Administration announced this week that the manufacturers of ...

FDA-Approved Sickle Cell Therapies From Bluebird Bio ... Life-Threatening Blood Cancer Risks Linked To Bluebird Bio's Skysona Gene Therapy The FDA is investigating reports of life-threatening ...